• U 46619: Strategic Insights for Translational Platelet and R

  2026-05-29

  This thought-leadership article from APExBIO provides translational researchers with an advanced roadmap for leveraging U 46619 (11,9 epoxymethano-prostaglandin H2) in dissecting platelet activation, vascular tone, and renal pathophysiology. We blend mechanistic detail, experimental best practices, and cross-study integration—bridging cardiovascular and renal research frontiers, contextualizing recent findings in ischemia-reperfusion injury, and offering actionable protocol guidance.

• Triamcinolone Protocols: Technical Guidance for Research Use

  2026-05-28

  Triamcinolone is a synthetic glucocorticoid agonist suited for in vitro studies of glucocorticoid signaling, anti-inflammatory research, and immunosuppression workflows. This compound is not appropriate for diagnostic or medical use, and requires careful attention to solubility and storage parameters for reliable experimental results.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows and Optimization

  2026-05-28

  (S)-(+)-Ibuprofen offers precise, reproducible COX inhibition for inflammation and pain research, combining high selectivity with robust tolerability. This guide translates fresh synthesis advances and experimental best practices into actionable workflows, troubleshooting, and comparative context for advanced nonsteroidal anti-inflammatory drug research.

• DOT1L Inhibition Enhances Immunomodulatory Drug Efficacy in

  2026-05-27

  This study demonstrates that DOT1L inhibition reprograms innate immunity in multiple myeloma (MM), leading to stronger responses to immunomodulatory drugs such as lenalidomide. The findings clarify mechanistic links between DOT1L, interferon signaling, and anti-myeloma activity, highlighting new avenues for epigenetic-based combination therapies.

• Sulfo-NHS-Biotin: Enabling Single-Cell Secretome Profiling

  2026-05-27

  Discover how Sulfo-NHS-Biotin empowers precise cell surface protein labeling and single-cell secretome analysis. This in-depth article explores advanced protocols and assay innovations, revealing unique insights distinct from standard applications.

• BMP4-GPX4 Axis Rescues Retinal Ganglion Cells in Glaucoma Mo

  2026-05-26

  This study demonstrates that the BMP4-GPX4 pathway mitigates ferroptosis and enhances retinal ganglion cell (RGC) survival and differentiation following retinal stem cell transplantation in a high intraocular pressure (IOP) glaucoma mouse model. The findings provide mechanistic insight into oxidative stress protection and offer a promising direction for neuroprotective strategies in glaucoma.

• BIRB 796 (Doramapimod): Shaping the Future of p38α MAPK Rese

  2026-05-26

  Explore how BIRB 796 (Doramapimod) redefines p38α MAPK inhibition by coupling mechanistic precision with translational potential. This article bridges advanced structural insights, experimental protocols, and evidence-based strategy to equip inflammation and apoptosis researchers with actionable guidance beyond standard reagent reviews.

• High-Throughput BBB Permeability Prediction via LLC-PK1-MDR1

  2026-05-25

  This study introduces a high-throughput in vitro blood-brain barrier (BBB) model that integrates LLC-PK1-MOCK/MDR1 cells and lysosomal trapping corrections to enhance the prediction of CNS drug permeability. The approach demonstrates strong correlation with in vivo brain distribution, providing a robust tool for early-stage CNS drug screening and prioritization.

• Applied Workflows with Substance P: Tachykinin Neuropeptide

  2026-05-25

  Unlock advanced pain and inflammation research with Substance P, a tachykinin neuropeptide uniquely suited for mechanistic and translational studies. This guide details optimized protocols, troubleshooting tips, and the latest spectral analytics, equipping labs to achieve reproducibility and new biological insight.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu

  2026-05-24

  The reference study introduces a robust protocol to generate human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) for pharmacokinetic research, offering a more physiologically relevant in vitro model for investigating oral drug metabolism. This advancement addresses limitations of traditional models and enables precise evaluation of CYP2C19 substrate metabolism in human-relevant systems.

• Modelling Pulmonary Drug Permeability: Advances in Biomimeti

  2026-05-23

  This study introduces a robust, mass spectrometry-compatible approach for modeling lung permeability of pharmaceuticals using biomimetic chromatography. By comparing immobilised artificial membrane (IAM) liquid chromatography and open tubular capillary electrochromatography (OT-CEC), the research establishes new standards for high-throughput permeability screening, with significant implications for respiratory drug development and inhaled corticosteroid studies.

• High-Throughput BBB Permeability Prediction with Surrogate M

  2026-05-22

  The reference study introduces a robust in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells combined with lysosomal trapping correction, enabling high-throughput and predictive screening of CNS drug candidates. This platform improves the reliability of BBB permeability assessment and streamlines early-stage CNS drug development workflows.

• Cimetidine as a Histamine-2 Receptor Antagonist in Barrier M

  2026-05-22

  Cimetidine’s distinct partial agonist profile enables advanced interrogation of H2 receptor signaling in both gastrointestinal cancer and blood-brain barrier (BBB) models. With high solubility and validated purity, it empowers reproducible, high-throughput workflows that stand apart from conventional H2 antagonists.

• ERAD-Hijacking Chimeras Enable Precise TM Protein Degradatio

  2026-05-21

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that hijacks ER-associated degradation (ERAD) for selective elimination of transmembrane proteins. This innovation addresses a critical gap in targeted protein degradation strategies, offering new avenues for research and potential therapeutic applications.

• ERAD-Engaging Chimeras Enable Selective TM Protein Degradati

  2026-05-21

  Song et al. (2026) introduce ERAD-engaging chimeras (ERADECs), a novel class of small molecules that hijack the ER-associated degradation pathway to induce selective degradation of transmembrane proteins. This approach overcomes previous technical barriers in targeted protein degradation and opens new avenues for disease-related membrane protein modulation.

483 records 12/33 page Previous Next First page 上5页 1112131415 下5页 Last page